EC Number |
Substrates |
Organism |
Products |
Reversibility |
---|
1.2.1.3 | (2E)-4-hydroxy-2-nonenal + NAD+ + H2O |
- |
Rattus norvegicus |
(2E)-4-hydroxy-2-nonenoic acid + NADH + H+ |
- |
? |
1.2.1.3 | (2E)-4-hydroxy-2-nonenal + NAD+ + H2O |
- |
Bos taurus |
(2E)-4-hydroxy-2-nonenoic acid + NADH + H+ |
- |
? |
1.2.1.3 | (E)-2-nonenal + NAD+ + H2O |
- |
Arabidopsis thaliana |
(E)-non-2-enoate + NADH + H+ |
- |
? |
1.2.1.3 | (R)-N-(3-(6-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b] thiophene-2-carboxamide + H2O + O2 |
i.e. GDC-0834, a Bruton's tyrosine kinase inhibitor, a potential treatment of rheumatoid arthritis. GDC-0834 |
Homo sapiens |
? |
compound is extensively metabolized by amide hydrolysis by both aldehyde oxidase and carboxylesterase |
? |
1.2.1.3 | (R)-trans-4-hydroxy-2-nonenal + NAD+ + H2O |
- |
Rattus norvegicus |
(2E,4R)-4-hydroxynon-2-enoic acid + NADH + H+ |
- |
? |
1.2.1.3 | (R)-trans-4-hydroxy-2-nonenal + NAD+ + H2O |
ALDH5A enantioselectively oxidizes (R)-trans-4-hydroxy-2-nonenal |
Rattus norvegicus |
(2E,4R)-4-hydroxynon-2-enoic acid + NADH + H+ |
- |
? |
1.2.1.3 | (S)-trans-4-hydroxy-2-nonenal + NAD+ + H2O |
- |
Rattus norvegicus |
(2E,4S)-4-hydroxynon-2-enoic acid + NADH + H+ |
- |
? |
1.2.1.3 | 1,3-dihydroxyacetone + NAD+ + H2O |
53.93% activity compared to acetaldehyde |
Sulfurisphaera tokodaii |
? + NADH + H+ |
- |
? |
1.2.1.3 | 1-formyl-6-methylpyrene + NAD+ |
- |
Homo sapiens |
6-methylpyrene 1-carboxylate + NADH + H+ |
- |
? |
1.2.1.3 | 1-formyl-6-methylpyrene + NAD+ + H2O |
- |
Homo sapiens |
6-methylpyrene-1-carboxylic acid + NADH + H+ |
- |
? |